A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Our writer reckons this tech-driven FTSE 250 investment trust has what it takes to outperform Rolls-Royce shares between now ...

The health sector is witnessing crucial developments including US turkey flu testing advocacy, WHO lobbying to retain US membership, and Medicare price negotiations involving major drugs. Meanwhile, ...

The FTSE 100 hit an all time high this week, and could reach 9,000 points by the end of 2025 according to the investment ...

Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...